Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial.

CONTEXT Hydroxycitric acid, the active ingredient in the herbal compound Garcinia cambogia, competitively inhibits the extramitochondrial enzyme adenosine triphosphate-citrate (pro-3S)-lyase. As a citrate cleavage enzyme that may play an essential role in de novo lipogenesis inhibition, G cambogia is claimed to lower body weight and reduce fat mass in humans. OBJECTIVE To evaluate the efficacy of G cambogia for body weight and fat mass loss in overweight human subjects. DESIGN Twelve-week randomized, double-blind, placebo-controlled trial. SETTING Outpatient weight control research unit. PARTICIPANTS Overweight men and women subjects (mean body mass index [weight in kilograms divided by the square of height in meters], approximately 32 kg/m2). INTERVENTION Subjects were randomized to receive either active herbal compound (1500 mg of hydroxycitric acid per day) or placebo, and both groups were prescribed a high-fiber, low-energy diet. The treatment period was 12 weeks. Body weight was evaluated every other week and fat mass was measured at weeks 0 and 12. MAIN OUTCOME MEASURES Body weight change and fat mass change. RESULTS A total of 135 subjects were randomized to either active hydroxycitric acid (n = 66) or placebo (n = 69); 42 (64%) in the active hydroxycitric acid group and 42 (61%) in the placebo group completed 12 weeks of treatment (P = .74). Patients in both groups lost a significant amount of weight during the 12-week treatment period (P<.001); however, between-group weight loss differences were not statistically significant (mean [SD], 3.2 [3.3] kg vs 4.1 [3.9] kg; P = .14). There were no significant differences in estimated percentage of body fat mass loss between treatment groups, and the fraction of subject weight loss as fat was not influenced by treatment group. CONCLUSIONS Garcinia cambogia failed to produce significant weight loss and fat mass loss beyond that observed with placebo.

[1]  M. Steelman Pharmacotherapy in the management of obesity. , 1997, JAMA.

[2]  P. Reimitz,et al.  Factors that influence the outcome of placebo-controlled antidepressant clinical trials. , 1997, Psychopharmacology bulletin.

[3]  COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS ( CPMP ) NOTE FOR GUIDANCE ON CLINICAL INVESTIGATION OF DRUGS USED IN WEIGHT CONTROL , 1997 .

[4]  John W. Graham,et al.  Analysis With Missing Data in Prevention Research , 1997 .

[5]  S B Heymsfield,et al.  Dual-energy X-ray absorptiometry body composition model: review of physical concepts. , 1996, The American journal of physiology.

[6]  R N Pierson,et al.  Techniques used in the measurement of body composition: an overview with emphasis on bioelectrical impedance analysis. , 1996, The American journal of clinical nutrition.

[7]  S. Heymsfield,et al.  Human Body Composition , 1996 .

[8]  J. Graham,et al.  Analysis with missing data in drug prevention research. , 1994, NIDA research monograph.

[9]  J. Graham,et al.  Advances in Data Analysis for Prevention Intervention Research. September 9-10, 1992. Proceedings. , 1994, NIDA research monograph.

[10]  G. Bray Use and Abuse of Appetite-Suppressant Drugs in the Treatment of Obesity , 1993, Annals of Internal Medicine.

[11]  W. H. Hall,et al.  Gastrointestinal Surgery for Severe Obesity. , 1991, Obesity surgery.

[12]  Jack Wang,et al.  Comparison of dual‐photon absorptiometry systems for total‐body bone and soft tissue measurements: Dual‐energy X‐rays versus gadolinium 153 , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  Leigh Burstein,et al.  MULTILEVEL INVESTIGATIONS OF SYSTEMATICALLY VARYING SLOPES: ISSUES, ALTERNATIVES, AND CONSEQUENCES , 1989 .

[14]  K. K. Sakariah,et al.  LIPID-LOWERING AND ANTIOBESITY EFFECT OF (-)HYDROXYCITRIC ACID , 1988 .

[15]  J. Garrow,et al.  The composition of excess weight in obese women estimated by body density, total body water and total body potassium. , 1984, Human nutrition. Clinical nutrition.

[16]  D. Rubin,et al.  Maximum likelihood from incomplete data via the EM - algorithm plus discussions on the paper , 1977 .

[17]  J. G. Hamilton,et al.  Inhibition of lipogenesis in rat liver by (-)-hydroxycitrate. , 1972, Archives of biochemistry and biophysics.

[18]  J. Lowenstein Effect of (-)-hydroxycitrate on fatty acid synthesis by rat liver in vivo. , 1971, The Journal of biological chemistry.

[19]  J. Lowenstein,et al.  Tricarballylate and hydroxycitrate: substrate and inhibitor of ATP: citrate oxaloacetate lyase. , 1969, Archives of biochemistry and biophysics.

[20]  J. Lowenstein Citrate and the conversion of carbohydrate into fat. , 1970, Biochemical Society symposium.

[21]  Lowenstein Jm Citrate and the conversion of carbohydrate into fat. , 1968 .

[22]  Y. S. Lewis,et al.  (−)-Hydroxycitric acid—the principal acid in the fruits of Garcinia cambogia desr. , 1965 .

[23]  C. Martius,et al.  Darstellung, physiologisches Verhalten und Bedeutung der (+)-Oxycitronensäure und ihrer Isomeren , 1941 .

[24]  E. Lippmann Ueber eine neue, im Rübensaft vorkommende Säure , 1883 .